<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215577</url>
  </required_header>
  <id_info>
    <org_study_id>SweLiv 1-2014</org_study_id>
    <nct_id>NCT02215577</nct_id>
  </id_info>
  <brief_title>ALPPS Versus PVE/PL</brief_title>
  <acronym>LIGRO</acronym>
  <official_title>Comparison of Two Different Models of Liver Growth Stimulation in Advanced Colorectal Liver Metastatic Disease, (LIGRO Trial) Enabling Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regionalt Cancercentrum Väst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionalt Cancercentrum Väst</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Title Comparison of two different models of liver growth stimulation in advanced
      colorectal liver metastatic disease, (LIGRO Trial) enabling liver resection

      Methodology Scandinavian Multiple Center Randomized Registry Based Clinical Trial

      Study duration The planned duration of study participation for an individual subject from
      inclusion to follow-up are 3 years

      Primary investigator:

      Per Sandstrom (Linköping)

      Number of subjects 100 patients randomized in a 1:1 randomization

      Diagnosis and main inclusion criteria Patients with colorectal liver metastasis requiring
      liver resection, but are not resectable in one step because of a future liver
      remnant/standardized total liver volume of &lt; 30 % extrahepatic metastatic disease is not an
      exclusion criteria if they can be addressed surgically in the future

      Overall goal To evaluate if the ALPPS approach is superior to PVE in enabling patients,
      primarily unresectable due to inadequate FLR, to be resected and reach an R0 situation with
      an acceptable level of complications and perioperative mortality.

      To evaluate if the ALPPS approach increases the growth rate of the liver compared to portal
      embolization or portal ligation leading to a shorter treatment period.

      In addition the investigators aim to study if ALPPS may reach these goals without detectable
      or improved differences in tumor activity (PFS and OS), but with a shorter recovery and a
      higher proportion of patients reaching R0.

      Hypothesis A higher proportion of patients can be resected with ALPPS counted as rate
      resected compared to the previously established methods with portal ligation or embolization.

      This increased resection rate will not reduce the R0 rate, or increase the rate of Clavien
      grade 4 complication or higher (H0).

      The ALPPS approach will increase the growth rate compared to portal embolization/ligation
      measured one week after the primary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical success rate, the rate of liver resection in each study arm</measure>
    <time_frame>8 weeks</time_frame>
    <description>For both the ALPPS and the portal vein embolization/ligation arm, resection is not allowed within the study if the patient is not reaching a future liver remnant of 30%.
For both groups carcinomatosis or more metastases making aiming radical resections impossible will be seen as failures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver growth rate</measure>
    <time_frame>At one week after primary intervention</time_frame>
    <description>Liver growth is measured with regard to the future liver remnant by measuring the kinetic growth rate by performing repeated CT or MRI at one week after portal vein embolization/ligation or after the first step of the ALPPS procedure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Radical resection rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Radical resection at resection line according to histopathology</description>
  </other_outcome>
  <other_outcome>
    <measure>Composite complication rate</measure>
    <time_frame>1 month after final surgery</time_frame>
    <description>Overall complications will be analysed as a composite endpoint (CEP) including: ascites, postresectional liver failure, bile leak, intra abdominal bleeding, intraabdominal abscess and mortality, all with a Clavien score of at least 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment time</measure>
    <time_frame>8 weeks</time_frame>
    <description>Treatment time in days from PVE/PL or date of ALPPS op 1 until date of leaving hospital after final surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Progression free survival according to randomization group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 months after last inclusion</time_frame>
    <description>Overall survival after inclusion</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months post final resection</time_frame>
    <description>Quality of life is measured by EORTC QLQ C-30 EQ5D ar 1,6,12,24 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health economy</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>An analysis with regard to hospitalisation rate and number of days in-ward between randomization arm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>In-situ split with portal vein ligature</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-situ liver split at time when portal vein ligature is performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Portal embolization or ligation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In-situ split</intervention_name>
    <description>The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.</description>
    <arm_group_label>In-situ split with portal vein ligature</arm_group_label>
    <other_name>ALPPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Portal embolization or ligation</intervention_name>
    <description>Portal vein embolization is performed according to the intervention used at the different sites.</description>
    <arm_group_label>Portal embolization or ligation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. By liver tumor board found accepted for inclusion

          2. Patients with a tumor burden of colorectal liver metastasis

          3. Signed informed content

          4. Colorectal liver metastatic disease with an estimated FLR/sTLV of &lt;30%

          5. Primary tumor and any extrahepatic disease possible to resect in patients with liver
             first approach or after resection of primary tumor.

        Exclusion Criteria:

          1. Cirrhosis

          2. Significant comorbidity rendering subjects unsuitable for major surgery

          3. Progressive disease after preoperative oncological treatment

          4. Age&lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Per Sandstrom, MD, PhD</last_name>
    <phone>+46 73 4058581</phone>
    <email>per.sandstrom@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magnus Rizell, MD, Phd</last_name>
    <phone>+46705259301</phone>
    <email>magnus.rizell@surgery.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departments of Surgical Gastroenterology and Transplantation</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Noergard Larsen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bard Rosak, MD, PhD</last_name>
      <email>brosok@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Bard Rosok, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Rizell</last_name>
    </contact>
    <investigator>
      <last_name>Magnus Rizell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Linkoping University Hospital</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Sandstrom, PhD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Per Sandstrom, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gert Lindell, MD, PhD</last_name>
      <phone>+46707190077</phone>
      <email>Gert.Lindell@skane.se</email>
    </contact>
    <investigator>
      <last_name>Gert Lindell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Isaksson, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bengt Isaksson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjarne Andnor, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bjarne Andnor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer, colorectal</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>portal vein</keyword>
  <keyword>embolization</keyword>
  <keyword>two-stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

